Literature DB >> 21974769

Spironolactone revisited.

Stergios A Polyzos, Jannis Kountouras, Christos Zavos, Georgia Deretzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21974769      PMCID： PMC8816482          DOI： 10.1111/j.1751-7176.2011.00484.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  17 in total

1.  Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile.

Authors:  E Zulian; P Sartorato; S Benedini; G Baro; D Armanini; F Mantero; C Scaroni
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

2.  Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet.

Authors:  Tsutomu Wada; Hiroki Kenmochi; Yusuke Miyashita; Motohiro Sasaki; Minoru Ojima; Masakiyo Sasahara; Daisuke Koya; Hiroshi Tsuneki; Toshiyasu Sasaoka
Journal:  Endocrinology       Date:  2010-03-08       Impact factor: 4.736

3.  The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy.

Authors:  Sachiko Matsumoto; Kohzo Takebayashi; Yoshimasa Aso
Journal:  Metabolism       Date:  2006-12       Impact factor: 8.694

4.  Comparison of effects of low dose of spironolactone and a thiazide diuretic in patients with hypertension treated with an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker.

Authors:  Miyashita Yutaka; Mizuo Mifune; Eiji Kubota; Hiroshi Itoh; Ikuo Saito
Journal:  Clin Exp Hypertens       Date:  2009-11       Impact factor: 1.749

5.  Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage.

Authors:  A S Bomback; P Muskala; E Bald; G Chwatko; M Nowicki
Journal:  Clin Nephrol       Date:  2009-12       Impact factor: 0.975

Review 6.  Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines.

Authors:  Stergios A Polyzos; Jannis Kountouras; Christos Zavos
Journal:  Curr Mol Med       Date:  2009-04       Impact factor: 2.222

7.  Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension.

Authors:  X Jeunemaitre; A Charru; G Chatellier; P Degoulet; J Julien; P F Plouin; P Corvol; J Ménard
Journal:  Am J Cardiol       Date:  1988-11-15       Impact factor: 2.778

8.  Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.

Authors:  Uzma F Mehdi; Beverley Adams-Huet; Philip Raskin; Gloria L Vega; Robert D Toto
Journal:  J Am Soc Nephrol       Date:  2009-11-19       Impact factor: 10.121

Review 9.  Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?

Authors:  Shweta Bansal; JoAnn Lindenfeld; Robert W Schrier
Journal:  Circ Heart Fail       Date:  2009-07       Impact factor: 8.790

10.  Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome.

Authors:  Levent Kebapcilar; Cuneyt Eftal Taner; Ayse Gul Kebapcilar; Ahmet Alacacioglu; Ismail Sari
Journal:  Arch Gynecol Obstet       Date:  2009-03-28       Impact factor: 2.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.